argenx
Willemstraat 5
Breda
4811 AH
United States
Tel: 31-0-10-763-030-488
Website: http://www.argenx.com/
Email: nfo@argenx.com
About argenx
argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.
YEAR FOUNDED:
2008
LEADERSHIP:
CEO: Tim Van Hauwermeiren
CFO: Eric Castaldi
CSO: Hans de Haard
CDO: Torsten Dreier
CMO: Nicolas Leupin
JOBS:
Please click here for Argenx job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
183 articles about argenx
-
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
4/16/2024
argenx SE announced that data from its Phase 3 ADHERE trial evaluating VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy were presented for the first time to the medical community during the Clinical Trials Plenary Session at the American Academy of Neurology Annual Meeting in Denver, CO.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
3/27/2024
argenx SE announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren’s disease, following the analysis of topline data from the Phase 2 RHO study.
-
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
3/26/2024
argenx SE announced that Japan’s Ministry of Health, Labour and Welfare approved VYVGART for intravenous use in adults with primary immune thrombocytopenia.
-
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
3/26/2024
argenx SE announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 7, 2024 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.
-
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
2/29/2024
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, reported financial results for the full year 2023 and provided a fourth quarter business update.
-
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
2/22/2024
argenx announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET to discuss its full year 2023 financial results and provide a fourth quarter business update.
-
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
2/20/2024
argenx SE announced that the U.S. Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for VYVGART Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy.
-
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
1/18/2024
argenx SE announced that Japan’s Ministry of Health, Labour and Welfare approved VYVDURA® injection for subcutaneous use for the treatment of adult patients with generalized myasthenia gravis, who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies.
-
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:00 a.m. PT.
-
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
12/20/2023
argenx SE announced topline results from the ADDRESS study evaluating efgartigimod subcutaneous in adults with pemphigus vulgaris and pemphigus foliaceus.
-
Argenx’s subcutaneous Fc receptor blocker efgartigimod was unable to induce a significantly higher rate of complete remission than placebo in the skin autoimmune disease. The company’s stock plummeted in response to the news.
-
The Dutch biotech’s stock dropped about 10% Tuesday morning after the company reported that its injectable Vyvgart Hytrulo missed the primary and secondary endpoints in an immune thrombocytopenia study.
-
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
11/28/2023
argenx SE announced topline results from the ADVANCE-SC study evaluating VYVGART Hytrulo in adults with primary immune thrombocytopenia.
-
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
11/16/2023
argenx SE today announced that the European Commission (EC) approved SC injectable VYVGART (efgartigimod alfa) as an add-on to standard therapy for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
-
argenx to Present at Upcoming November 2023 Investor Conferences
11/1/2023
Amsterdam, the Netherlands – argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that members of management will participate in several upcoming investor conferences in November.
-
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
11/1/2023
argenx SE announced 20 presentations of clinical trial and real-world data from studies of VYVGART® and VYVGART Hytrulo® in neuromuscular autoimmune disease.
-
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
10/31/2023
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced its third quarter 2023 financial results and provided a business update and outlook for the remainder of the year.
-
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
10/24/2023
argenx announced that it will host a conference call and audio webcast on Tuesday, October 31, 2023 at 1:30 pm CET to discuss its third quarter 2023 financial results and provide a business update.
-
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
9/21/2023
argenx SE announced that Health Canada has issued a Notice of Compliance authorizing VYVGARTⓇ for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.